Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.44 |
| ▸ | HTR1B | P28222 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446338 | 0.94 | KMT2A (0.52) | NPC1KMT2ATMEM97SIGMAR1PTGDR2 | |
| SCHEMBL5446453 | 0.93 | NPC1 (0.51) | NPC1KMT2ATMEM97SIGMAR1PTGDR2 | |
| SCHEMBL5456835 | 0.91 | NPC1 (0.49) | NPC1KMT2ATMEM97SIGMAR1PTGDR2 | |
| SCHEMBL5454903 | 0.91 | NPC1 (0.53) | NPC1KMT2ATMEM97SIGMAR1PTGDR2 | |
| SCHEMBL5449946 | 0.91 | NPC1 (0.47) | NPC1KMT2ATMEM97SIGMAR1PTGDR2 | |
| SCHEMBL5446341 | 0.91 | MAPT (0.59) | NPC1KMT2AMAPTHTR1AABCB1 | |
| SCHEMBL5449891 | 0.91 | GFER (0.47) | NPC1KMT2ATMEM97SIGMAR1PTGDR2 | |
| SCHEMBL5461787 | 0.91 | GFER (0.50) | NPC1KMT2ATMEM97SIGMAR1MAPT | |
| SCHEMBL5456816 | 0.90 | HTR7 (0.49) | NPC1KMT2ATMEM97SIGMAR1PTGDR2 | |
| SCHEMBL5455136 | 0.90 | NPC1 (0.49) | NPC1KMT2ATMEM97SIGMAR1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | NPC1 1664/4885KMT2A 1271/4885TMEM97 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.